View Future GrowthPRF Technologies 過去の業績過去 基準チェック /06PRF Technologiesの収益は年間平均-11.1%の割合で減少していますが、 Pharmaceuticals業界の収益は年間 増加しています。収益は年間8.7% 105.5%割合で 増加しています。主要情報-11.13%収益成長率80.65%EPS成長率Pharmaceuticals 業界の成長5.95%収益成長率105.50%株主資本利益率-54.06%ネット・マージン-28,458.82%前回の決算情報31 Dec 2025最近の業績更新更新なしすべての更新を表示Recent updatesPRF Technologies Ltd. Announces FDA Clearance Of IND Application For OcuRing-K Phase II Clinical TrialApr 30Less than half of directors are independent Mar 12PRF Technologies Ltd. Files Its First Patent Application for Solar Plant Micro-Climate Forecast Modeling Designed to Improve Energy Production Forecast AccuracyJan 21New major risk - Share price stability Jan 20PainReform Ltd. and LayerBio, Inc. Announces Safety Data Supporting the Continued Development of OcuRing-K Drop-less, Sustainable-Release Ocular Drug Delivery Platform for Use in Cataract SurgeryJan 13PainReform Ltd.'s Deepsolar Launches Smart TDD, A Next-Generation Solar Due Diligence Service Targeting the $60B+ Global Solar Asset M&A MarketJan 06Painreform Ltd. Announces Its Pharmaceutical Division Has Completed an R&D Assessment of Layerbio's Proprietary Drop-Less, Sustained-Release Ocular Drug-Delivery PlatformDec 11PainReform Ltd. Commences Development for OcuRing™?-K Phase II Trial, LayerBio's Drop-Less Sustained-Release Ocular TherapyDec 03PainReform Ltd., Annual General Meeting, Dec 30, 2025Nov 26PainReform's DeepSolar Advances Development of its AI-Driven Automated Reporting Engine for Solar-Asset AnalysisNov 13New major risk - Share price stability Aug 19New major risk - Revenue and earnings growth Apr 16PainReform Ltd. (NasdaqCM:PRFX) completed the acquisition of Business Activities Associated with the DeepSolar Technology of BladeRanger Ltd.Mar 07New minor risk - Financial data availability Mar 03PainReform Ltd. (NasdaqCM:PRFX) entered into a business acquisition agreement to acquire Business Activities Associated with the DeepSolar Technology of BladeRanger Ltd for ILS 1.8 million.Feb 19PainReform Ltd. Provides Further Update on Phase 3 Clinical Trial of PRF-110Dec 27Painreform Ltd. Announces CFO ChangesDec 06PainReform Ltd. Announces Initial Topline Data for PRF-110 Phase 3 Clinical TrialNov 20PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity RequirementNov 08PainReform Ltd. has filed a Follow-on Equity Offering in the amount of $1.35 million.Oct 17PainReform Ltd., Annual General Meeting, Sep 30, 2024Aug 29PainReform Ltd. Announces Successful Determination of Optimal Delivery Method for PRF-110 in Bunionectomy ProceduresAug 22painReform Ltd. Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy StudyAug 20New major risk - Financial position Aug 18PainReform Ltd. Announces Development and Successful Manufacturing of New Formulations Providing Anti-Inflammatory and Extended Analgesic EffectsAug 13PainReform Ltd. Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher DosesAug 08PainReform Ltd. Announces Favorable Wound Healing Data in Human Clinical Trials for PRF-110Aug 06PainReform Ltd. Announces New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room TemperatureAug 02PainReform Ltd. Files Patent Covering Highly Scalable Manufacturing Process for PRF-110 Following Successful Completion and TestingJul 25PainReform Ltd. Completes Enrollment in the Second Part of Its Phase 3 Bunionectomy Trial for Prf-110Jun 26New major risk - Share price stability Jun 14PainReform Ltd. has completed a Follow-on Equity Offering in the amount of $7.999045 million.Apr 19Painreform Ltd. Announces Groundbreaking Results from New Studies Demonstrating the Superior In-Vitro Release Rates of PRF-110Apr 12PainReform Ltd. Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in BunionectomyApr 02PainReform Ltd. has filed a Follow-on Equity Offering in the amount of $5 million.Mar 02New major risk - Shareholder dilution Jan 21Insufficient new directors Oct 01PainReform Ltd. Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master FileSep 13PainReform Ltd. Announces Selection for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, HungarySep 08We're Keeping An Eye On PainReform's (NASDAQ:PRFX) Cash Burn RateJul 03New major risk - Revenue and earnings growth Jun 11PainReform Ltd. Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy SurgeryJun 08New major risk - Financial position Jun 08PainReform Ltd. Announces Positive Pharmacokinetic (PK) Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy SurgeryMay 19PainReform Ltd., Annual General Meeting, Jun 08, 2023May 05PainReform Announces Receipt of Extension to Meet the Nasdaq’s Minimum Bid Price RequirementFeb 09PainReform Ltd., Annual General Meeting, Dec 29, 2022Nov 26Price target decreased to US$3.00 Nov 16PainReform Ltd. Provides Further Update on Manufacturing of PRF-110Nov 09PainReform Ltd. Provides PRF-110 Manufacturing UpdateOct 06PainReform Announces Receipt of Nasdaq Minimum Bid Price NotificationAug 17PainReform reports results Aug 16Price target decreased to US$3.00 Apr 27We're Hopeful That PainReform (NASDAQ:PRFX) Will Use Its Cash WiselySep 19Companies Like PainReform (NASDAQ:PRFX) Are In A Position To Invest In GrowthMay 23Forecast to breakeven in 2025 May 22PainReform Ltd. announced that it has received $5.999992 million in fundingMar 21Director has left the company Mar 10PainReform Ltd. announced that it expects to receive $5.999992 million in fundingMar 09PainReform Ltd. Announces Resignation of Assif Stoffman from Board of DirectorsMar 04New 90-day high: US$5.66 Feb 10PainReform Ltd. Appoints Rita Keynan as Vice President of Pharmaceutical OperationsJan 08New 90-day low: US$4.06 Jan 07PainReform Appoints Ilan Hadar as Chief Executive OfficerNov 24PainReform Ltd. Welcomes Ellen Baron as A Member of Board of DirectorsNov 14PainReform Ltd. Appoints Augustine Lawlor as Member of Board of DirectorsNov 10PainReform Ltd. has completed an IPO in the amount of $20 million.Sep 02収支内訳PRF Technologies の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NasdaqCM:PRFX 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Dec 250-53130 Sep 250-43130 Jun 250-43131 Mar 250-103731 Dec 240-1531230 Sep 240-1931430 Jun 240-1831531 Mar 240-133931 Dec 230-94630 Sep 230-84530 Jun 230-104631 Mar 230-94531 Dec 220-94430 Sep 220-74330 Jun 220-74331 Mar 220-74331 Dec 210-74330 Sep 210-74330 Jun 210-53231 Mar 210-52131 Dec 200-41030 Sep 200-41030 Jun 200-41031 Mar 200-41031 Dec 190-21030 Sep 190-20030 Jun 190-20031 Mar 190-20031 Dec 180-200質の高い収益: PRFXは現在利益が出ていません。利益率の向上: PRFXは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: PRFXは利益が出ておらず、過去 5 年間で損失は年間11.1%の割合で増加しています。成長の加速: PRFXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: PRFXは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( -3.3% ) と比較することは困難です。株主資本利益率高いROE: PRFXは現在利益が出ていないため、自己資本利益率 ( -54.06% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日(UTC時間)企業分析2026/05/05 15:32終値2026/05/05 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PRF Technologies Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Jason McCarthyMaxim GroupNazibur RahmanMaxim Group
PRF Technologies Ltd. Announces FDA Clearance Of IND Application For OcuRing-K Phase II Clinical TrialApr 30
PRF Technologies Ltd. Files Its First Patent Application for Solar Plant Micro-Climate Forecast Modeling Designed to Improve Energy Production Forecast AccuracyJan 21
PainReform Ltd. and LayerBio, Inc. Announces Safety Data Supporting the Continued Development of OcuRing-K Drop-less, Sustainable-Release Ocular Drug Delivery Platform for Use in Cataract SurgeryJan 13
PainReform Ltd.'s Deepsolar Launches Smart TDD, A Next-Generation Solar Due Diligence Service Targeting the $60B+ Global Solar Asset M&A MarketJan 06
Painreform Ltd. Announces Its Pharmaceutical Division Has Completed an R&D Assessment of Layerbio's Proprietary Drop-Less, Sustained-Release Ocular Drug-Delivery PlatformDec 11
PainReform Ltd. Commences Development for OcuRing™?-K Phase II Trial, LayerBio's Drop-Less Sustained-Release Ocular TherapyDec 03
PainReform's DeepSolar Advances Development of its AI-Driven Automated Reporting Engine for Solar-Asset AnalysisNov 13
PainReform Ltd. (NasdaqCM:PRFX) completed the acquisition of Business Activities Associated with the DeepSolar Technology of BladeRanger Ltd.Mar 07
PainReform Ltd. (NasdaqCM:PRFX) entered into a business acquisition agreement to acquire Business Activities Associated with the DeepSolar Technology of BladeRanger Ltd for ILS 1.8 million.Feb 19
PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity RequirementNov 08
PainReform Ltd. Announces Successful Determination of Optimal Delivery Method for PRF-110 in Bunionectomy ProceduresAug 22
PainReform Ltd. Announces Development and Successful Manufacturing of New Formulations Providing Anti-Inflammatory and Extended Analgesic EffectsAug 13
PainReform Ltd. Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher DosesAug 08
PainReform Ltd. Announces New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room TemperatureAug 02
PainReform Ltd. Files Patent Covering Highly Scalable Manufacturing Process for PRF-110 Following Successful Completion and TestingJul 25
PainReform Ltd. Completes Enrollment in the Second Part of Its Phase 3 Bunionectomy Trial for Prf-110Jun 26
Painreform Ltd. Announces Groundbreaking Results from New Studies Demonstrating the Superior In-Vitro Release Rates of PRF-110Apr 12
PainReform Ltd. Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in BunionectomyApr 02
PainReform Ltd. Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master FileSep 13
PainReform Ltd. Announces Selection for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, HungarySep 08
PainReform Ltd. Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy SurgeryJun 08
PainReform Ltd. Announces Positive Pharmacokinetic (PK) Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy SurgeryMay 19